Please assess the completion status of the following clinical trial:

Trial Title: Speed of Recovery of Reversal of Neuromuscular Blockade in Geriatric Patients Undergoing Spine Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Posterior spinal surgery~2. Age ≥ 65 years~3. American Society of Anesthesiologists (ASA) grade I-III~Exclusion Criteria:~1. Inability to obtain written informed consent~2. Allergy to rocuronium or anesthetic agents used in the protocol~3. Known or suspected neuromuscular disorders~4. Significant renal disease with a serum creatinine ≥ 2 mg/dl~5. Significant liver disease~6. A family history of malignant hyperthermia

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sugammadex group (Type: EXPERIMENTAL): 2 mg/kg of sugammadex, IV once at the end of the surgery. Dosing will be based on actual body weight not ideal body weight.
- Neostigmine group (Type: ACTIVE_COMPARATOR): 50 micrograms/kg (not to exceed 5 mg) and glycopyrrolate, 10 micrograms/kg (not to exceed 1 mg), IV once at the end of the surgery.~Dosing will be based on actual body weight not ideal body weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).